Bausch + Lomb Corporation (BLCO)
NYSE: BLCO · IEX Real-Time Price · USD
-0.76 (-5.07%)
At close: Apr 12, 2024, 4:00 PM
+0.04 (0.28%)
After-hours: Apr 12, 2024, 7:58 PM EDT

Company Description

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally.

It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.

Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases.

The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery.

The company sells its products and services through direct sales forces and independent distributors.

Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Bausch + Lomb Corporation
Bausch + Lomb logo
Country Canada
Founded 1853
IPO Date May 6, 2022
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 13,300
CEO Brenton L. Saunders J.D.

Contact Details

520 Applewood Crescent
Vaughan, A6 L4K 4B4
Ontario, Canada
Phone 908-541-5456

Stock Details

Ticker Symbol BLCO
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001860742
CUSIP Number 071705107
ISIN Number CA0717051076
SIC Code 3851

Key Executives

Name Position
Osama A. Eldessouky Executive Vice President and Chief Financial Officer
Dr. Yehia Hashad M.D. Executive Vice President of Research and Development and Chief Medical officer
Brenton L. Saunders J.D. Chief Executive Officer and Chairman
Alan Waterhouse CPFA, MBA Executive Vice President and Chief Supply Chain and Operations Officer
Frederick J. Munsch Senior Vice President, Controller and Chief Accounting Officer
A. Robert D. Bailey Executive Vice President and Chief Legal Officer
Jonathon L. Kellerman Chief Compliance Officer
T.J. Crawford Chief Communications Officer
Dr. Manisha A. Narasimhan Ph.D. Chief Corporate Development and Digital Officer
Asli Gevgilili Executive Vice President and Chief Human Resources Officer

Latest SEC Filings

Date Type Title
Feb 28, 2024 8-K Current Report
Feb 21, 2024 10-K Annual Report
Feb 21, 2024 8-K Current Report
Nov 13, 2023 8-K/A [Amend] Current report
Nov 7, 2023 8-K/A [Amend] Current report
Nov 1, 2023 10-Q Quarterly Report
Nov 1, 2023 8-K Current Report
Sep 29, 2023 8-K Current Report
Sep 14, 2023 8-K Current Report
Sep 11, 2023 8-K Current Report